Innovation | Novartis United States of America

Media Release
Dec 15, 2020
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
Media Release
Dec 09, 2020
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
Media Release
Dec 08, 2020
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
Media Release
Dec 07, 2020
Novartis and Amgen partner with Karamo Brown to support and empower people living with migraine
Media Release
Dec 01, 2020
Novartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps
Media Release
Nov 19, 2020
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Media Release
Nov 13, 2020
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
Media Release
Nov 05, 2020
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
Media Release
Oct 03, 2020
Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
Media Release
Sep 16, 2020
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
Media Release
Sep 11, 2020
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
Media Release
Aug 30, 2020
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran

‹ Previous page
1
…
4
5
6
7
8
9
10
…
50
› Next page